CYAD-103

N/A

Report date: 2024/04/30 16:21:47

Base Information

Drug NameCYAD-103

Drug Alias NameCYAD-103

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-NKG2D ligandsT lymphocyte replacementsImmunologic cytotoxicity

TargetsNKG2D ligands

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCelyad Oncology SA

China Registration ClassN/A

Develop Information

Active CompaniesCelyad Oncology SA

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A